期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

细胞色素P4502D6酶基因多态性与抗精神病药临床效应 被引量：1

暂未订购
导出
摘要 目前认为，细胞色素P4502D6酶（CYP2D6）基因多态性可能与精神分裂症的易感性无关。但CYP2D6酶参与绝大多数抗精神病药（尤其是利培酮、氟哌啶醇等）的代谢，进而影响药物疗效、副反应及药物之问的相互作用。因而研究CYP2D6基因多态性与其表型活性之间的关系，对于抗精神病药临床合理应用具有指导意义。
作者 刘铁榜 李凌江 周云飞 吴怀安 杨孔军 杨海晨
机构地区 中南大学湘雅二院精神卫生研究所 深圳市精神卫生研究所
出处 《中国行为医学科学》 CSCD 2007年第4期383-384,共2页 Chinese Journal of Behavioral Medical Science
关键词 细胞色素P4502D6 酶基因多态性 抗精神病药 临床效应 CYP2D6 药物疗效 精神分裂症 氟哌啶醇
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献16

  • 1Chen CH, Hung CC, Wei FC, et al. Debrisoquine 4-hydroxylase(CYP2D6) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan. Psychiatr Genet,2001,11 : 153-155.
  • 2Roh HK, Chung JY, Oh DY,et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Chn Phannacol,2001,52 :26.5-271.
  • 3Shimoda K, Morita S, Yokono A,et al. CYP2D6 * 10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients.Ther Drug Monit,2000,22:392-396.
  • 4Saito M, Yasui-Furukori N, Kaneko S. et al. Clinical pharmacogenetics in the treatment of schizophrenia. Nihon Shinkei Seishin Yakurigaku Zasshi ,2005,25:129-135.
  • 5Ozaki N. Pharmacogenetics of antipsychoatics. Nagoya J Med Sci ,2004,67 : 1-7.
  • 6Scordo MG, Spina E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics ,2002 , 3:201-218.
  • 7钟智勇,张晋碚,温盛霖,黄兴兵,魏钦令,吴小立.抗精神病药合并盐酸丁咯地尔治疗Ⅱ型精神分裂症疗效与IL-2和IL-6水平变化的研究[J].中国行为医学科学,2006,15(2):131-133. 被引量：4
  • 8de Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry,2005,66 : 15-27.
  • 9Brockmoller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther, 2002 , 72 : 438-452.
  • 10Inada T, Senoo H, lijima Y,et al. Cytoehrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatr Genet,2003,13:163-168.

二级参考文献21

  • 1Ketter TA, Wang PW, Nowakowska C. New medication treatment options for bipolar disorders. Acta Psychiat Scand , 2004,110:18-33.
  • 2Shulman RW, Singh A, Shulman KI, et al. Treatment of elderly institutionalized bipolar patients with clozapine. Psychopharmacology Bulletin,1997,33:113-117.
  • 3Laloude . Evaluating antipsychotic medications : predictions of clinical effectiveness . Can J Psychiat , 2003, 48:4-12.
  • 4Hirschfeld RM. The efficacy of atypical antipsychotics in bipolar disorders. J Clin Psychiatry, 2003,64:15-21.
  • 5Shelton RC. The use of antidepressants in novel combination therapies.J Clin Psychiatry, 2003,64:14-18.
  • 6Coryell W. The treatment of psychotic depression . J Clin Psychiatry,1998,59:22-27.
  • 7Mondimore FM, Fuller GA, DePaulo JR. Drug combinations for mania .J Clin Psychiatry, 2003,64: 25-31.
  • 8Grof P. Selecting effective long-term treatment for bipolar patients :monotherapy and combinations . J Clin Psychiatry,2003,64:53-61.
  • 9Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry ,2003,64:5-12.
  • 10Schatzberg AF. New approaches to managing psychotic depression. J Clin Psychiatry, 2003,64:19 -23.

共引文献3

同被引文献11

  • 1付燕,范长河,赵振环,李立华,胡三红,张璐璐,朱蔚林,施玉旋,陆欣乔.CYP2D6基因多态性与精神分裂症患者迟发性运动障碍的关联研究[J].中国行为医学科学,2006,15(1):36-37. 被引量：10
  • 2Chen CH, Hung C, Wei FC, et al. Debrisoquine 4-hydroxylase ( CYP2D6 ) genetic polymorphisms and susceptibility to schizophrenia in Chinese patients from Taiwan. Psychiatr Genet,2001,11:153-155.
  • 3Wang SL, Huang JD, Lai MD,et al. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin Phamacol Ther, 1993,53 : 410-415.
  • 4Gonzalez FJ, Meyer UA. Molecular genetics of the debrisonquine sparteine polymorphism. J Clin. Phamacol Ther,1991,50 :233-236.
  • 5Daly AK, Cholerton S. Genotyping for polymorphism in xenobioticmetabolism as a predictor of disesse susceptibility. Environ Health Prespect, 1994,102:56-61.
  • 6Ozaki N. Pharmacogenetics of antipsychoatics. Nagoya J Med Sci ,2004 , 67 : 1-7.
  • 7Saito M, Yasui-Furukori N, Kaneko S. et al. Clinical pharmacogenetics in the treatment of schizophrenia Nihon Shinkei Seishin Yakurigaku Zasshi,2005,25 : 129-135.
  • 8Scordo MG, Spina E. Cytoehrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics,2002 ,3:201-218.
  • 9Kores Plesnicar B, Zalar B, Breskvar K, et al. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol,2006,14 : 121-125.
  • 10刘铁榜,臧德馨.难治性精神分裂症[J].临床精神医学杂志,2000,10(2):114-116. 被引量：91

引证文献1

二级引证文献1

中国行为医学科学
2007年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部